NCT02630017 (MOBE) is a Phase 2 clinical trial of ADHD methylphenidate first, placebo second in ADHD, sponsored by University of Arkansas.

Who is sponsoring NCT02630017?

NCT02630017 is sponsored by University of Arkansas.

What drugs are being tested in NCT02630017?

Interventions in NCT02630017: ADHD methylphenidate first, placebo second, ADHD placebo first, methylphenidate second, Non-ADHD methylphenidate first, placebo second, Non-ADHD placebo first, methylphenidate second.

Is NCT02630017 still recruiting?

NCT02630017 is currently completed. Last updated 27 August 2021.

Are results published for NCT02630017?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-08-27 · How we verify

NCT02630017: MOBE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Motivated Behavior in Adults With and Without ADHD

Completed Phase 2 Results posted Last updated 27 August 2021

What this trial tests

Phase 2 trial testing ADHD methylphenidate first, placebo second in ADHD in 51 participants. Completed in 21 September 2018.

Timeline

7 March 2016

Primary endpoint
21 September 2018

21 September 2018

Quick facts

Lead sponsor	University of Arkansas
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	51
Start date	7 March 2016
Primary completion	21 September 2018
Estimated completion	21 September 2018
Sites	2 locations across United States

Drugs / interventions tested

ADHD methylphenidate first, placebo second — full drug profile →
ADHD placebo first, methylphenidate second — full drug profile →
Non-ADHD methylphenidate first, placebo second — full drug profile →
Non-ADHD placebo first, methylphenidate second — full drug profile →

Conditions studied

ADHD — all drugs for ADHD →

Sponsor

University of Arkansas

Who can join

Adults 18 to 45, any sex, with ADHD. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of High-effort Selections in the Effort-based Decision Making Task Primary · 1 hour post drug (or placebo) administration for each study session

Number of high-effort selections in the effort-based decision making task from the placebo to the methylphenidate condition. This is a decision-making task where participants make high- or low-effort choices to earn a small financial reward. High-effort selections require 100 button presses with non-dominant hand pinky finger and low-effort selections require 30 button presses with dominant hand index finger (within 15 seconds). The number of high effort selections are summed across 50 trials of the task. This task measures the willingness to perform effort in relation to changing reward magni

Group	Value	95% CI
ADHD Subjects, Placebo Condition	16.4	± 2.2
ADHD Subjects, Methylphenidate Condition	21.35	± 1.9
Non-ADHD Subjects, Placebo Condition	20.45	± 2.2
Non-ADHD Subjects, Methylphenidate Condition	19.8	± 1.9

Sponsor's own description

To investigate the effects of methylphenidate on motivated behavior in adults with and without ADHD

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Methylphenidate increases willingness to perform effort in adults with ADHD.
Addicott MA, Schechter JC, Sapyta JJ, Selig JP, et al · · 2019 · cited 15× · PMID 31226260 · DOI 10.1016/j.pbb.2019.06.008

Verify or expand the search:

Other recruiting trials for ADHD

Currently open trials in the same condition.

NCT07314333 — A Trial to Assess How Centanafadine Interacts With Stimulants in the Body · Phase 1 · recruiting
NCT07262853 — Dual Executive Function Training Package · NA · recruiting
NCT07291453 — Loving Habits: A Feasibility Study of a Support Program for Building New Parent-child Behavioral Habits · NA · recruiting
NCT07281092 — Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) · NA · recruiting
NCT07219810 — Accelerated iTBS Targeting of Working Memory Versus Inhibitory Control in Adolescent ADHD · NA · recruiting

Other University of Arkansas trials

Trials by the same sponsor.

NCT07029776 — MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma · Phase 2 · not yet recruiting
NCT07341399 — Essential Amino Acid Supplementation in Adult Spinal Deformity Patients · NA · not yet recruiting
NCT07071766 — Improving Outcomes for Early Postpartum Mothers in Outpatient MOUD Treatment · NA · recruiting
NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
NCT06604065 — Essential Amino Acids and Parkinsons Disease · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02630017 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Arkansas
Last refreshed: 27 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02630017.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing